“Let’s take a look at your PSA.” That is a phrase that more and more men could be hearing from their doctors. The prostate-specific antigen or PSA is the first line of defense against prostate cancer. It’s a blood test used in screening male patients, and it’s a very serious issue. A recent survey from the National Cancer Institute found that there were close to 218,000 new diagnoses of prostate cancer last year. Of that number, over 32,000 succumbed to the deadly disease. Thanks to improvements in prostate cancer testing, the PSA is becoming an increasingly effective tool for early detection.
An elevated PSA level doesn’t always mean that cancer is present. Those results could be due to an enlarged prostate or infection. It is also difficult to specify which type of cancer might be present with the PSA screening alone. The results of a PSA screening could indicate the need of a biopsy. This is where the issue of health informatics comes into play. The goal should be to find ways not to miss the presence of cancer. There are clinical test trials going on today involving the PCA3 test and a screening of the TMPRSS2 and ERG genes present in urine.
Combining these various tests can provide a complete diagnosis for a patient. It is recommended that men between the ages of 40 and 50 begin to have annual prostate cancer exams. Beyond the physical exam, it might be beneficial to add the PSA to your annual check-up. You could also ask about additional screening options.





